Oxazolidinone Antibacterial Drug Class List

Drugs in Drug Class: Oxazolidinone Antibacterial

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	ZYVOX	linezolid	TABLET;ORAL	021130-001	Apr 18, 2000		DISCN	Yes	No
Pfizer	ZYVOX	linezolid	TABLET;ORAL	021130-002	Apr 18, 2000		DISCN	Yes	No
Pfizer	ZYVOX	linezolid	SOLUTION;INTRAVENOUS	021131-001	Apr 18, 2000	AP	RX	Yes	No

Market Dynamics and Patent Landscape for Oxazolidinone Antibacterial Drugs (Linezolid, Tedizolid, Radezolid and Next-Gen Agents)

Last updated: July 18, 2026

Oxazolidinone antibacterial IP is anchored by older, widely used core molecules (linezolid; tedizolid) and by a smaller set of later-stage successors (for example, radezolid). Commercial value clusters around gram-positive and multidrug-resistant indications, while patent duration and FDA exclusivity timing drive the cadence of generic and “authorized” competition. The patent estate for each marketed oxazolidinone typically spans (1) polymorphs and solid-state forms, (2) formulations, (3) manufacturing processes, and (4) dosing regimens and method-of-use. For entry-risk work, the practical question is less “is there any patent” and more “what specific dosage form and strength is the proposed generic, and which Orange Book-listed patents and likely non-Orange-Book process or polymorph claims survive.”

---

Which oxazolidinone antibiotics have the strongest patent protection today (linezolid vs tedizolid vs investigational oxazolidinones)?

Answer: Patent protection strength depends on whether the current “commercial product” is still supported by active Orange Book-listed patents (for generics entry barriers) and whether meaningful non-Orange-Book claims remain in the same jurisdiction for the relevant form factor (tablet vs oral suspension vs IV). In oxazolidinones, linezolid’s initial patents are largely matured, while tedizolid has more recent filings that can extend method-of-use, solid-state, and formulation coverage into later years in key markets. Next-generation candidates (such as radezolid) usually have IP that is more “still-to-be-proven” and depends on ongoing life-cycle filings and exclusivity periods.

H2 How do linezolid and tedizolid patent estates differ in duration and claim scope?

Answer:

• Linezolid: early-to-mid-life patents on the core scaffold and later-life-cycle patents often center on specific polymorphs, hydrated forms, and formulations. As those age, the practical litigation and regulatory risk shifts from “core compound” patents to “product-specific” ones.
• Tedizolid: typically benefits from a later development timeline and a patenting strategy that places more emphasis on solid-state forms and dosing/regimen-linked claims for phosphate or free-base equivalents and for the marketed extended coverage around dose and administration constraints.

H3 Which jurisdictions matter for oxazolidinone freedom-to-operate (FTO) and Paragraph IV risk?

For market entry and litigation planning, the highest practical focus is:

• U.S. (Orange Book + Hatch-Waxman + Paragraph IV) for generic entry timing and settlement dynamics.
• Europe (EMA + national enforcement) for polymorph/formulation enforcement in member states where launches occur.
• UK and selected high-enforcement systems for solid-state and process claims.

---

When does oxazolidinone antibacterial patent exclusivity expire (U.S. timelines for generic entry)?

Answer: In the U.S., launch timing is typically controlled by (1) expiration of Orange Book-listed patents that tie to the NDA, and (2) FDA exclusivity periods (including new chemical entity/exclusivity, new clinical investigation where applicable, and orphan exclusivity where applicable). For oxazolidinones, the most actionable “when” is the last Orange Book patent date for the exact dosage forms and strengths in the Orange Book, plus any listed pediatric exclusivity extensions where applicable.

H2 What is the Orange Book status of linezolid and tedizolid?

Answer: Orange Book status drives Paragraph IV strategy:

• If Orange Book patents remain active for a specific dosage form/strength, Paragraph IV filings can trigger automatic stays and increase settlement leverage.
• Once patents expire, generic approvals can proceed without litigation-driven delay, subject to regulatory requirements.

H3 How does pediatric exclusivity affect oxazolidinone launch timing?

Pediatric exclusivity can extend the effective exclusivity window by triggering a post-approval extension tied to pediatric study completion. In oxazolidinones, this is most relevant when the NDA holder has submitted qualifying pediatric data and the FDA grants pediatric exclusivity that overlays patent expiry.

---

What patents protect oxazolidinone formulations and solid-state forms (polymorphs, hydrates, salts, prodrugs)?

Answer: For oxazolidinones, the highest frequency “barrier patents” in late-life life-cycle strategies are solid-state and formulation claims rather than broad compound claims, because compound claims age out while product-specific claims can persist.

H2 What formulations are protected by oxazolidinone patents (tablets, suspensions, IV solutions)?

Answer: The core pattern is:

• Oral dosage form patents: include tablet compositions, granulation processes, disintegration and dissolution targets, and excipient systems linked to stability and bioavailability.
• IV dosage form patents: include concentrate compositions, buffering systems, sterilization stability, and manufacturing steps ensuring acceptable particle control and degradation profiles.
• Oral suspension patents: focus on particle size management, suspending agents, and long-term chemical stability.

H3 Which claim types show up most often for oxazolidinones?

In practice, oxazolidinone IP frequently includes:

1. Polymorph and hydrate form claims (including “form” identifiers and stability characterizations).
2. Salt/prodrug or phosphate complex claims where applicable (tedizolid phosphate is a common life-cycle target).
3. Process claims for crystallization and drying (morphology control).
4. Method-of-use claims for specific dosing regimens and patient subgroups (where enforcement remains active).

---

How strong is the patent estate for linezolid and tedizolid (litigation-resilient claim sets)?

Answer: Strength is determined by enforceability and survivability against standard invalidity theories: obviousness over prior art, lack of enablement, and indefiniteness. Oxazolidinones often maintain litigation strength when their solid-state forms are supported by robust characterization and when claim scope ties to specific stability or manufacturing outcomes.

H2 What factors make oxazolidinone polymorph patents more enforceable?

Answer:

• Clear, reproducible identification of the polymorph/hydrate/form (XRD patterns, DSC, Raman, solid-state NMR where used).
• Tight linkage between the claimed form and observed stability advantages.
• Manufacturing processes that reliably generate the claimed form.

H3 Are oxazolidinone process patents a higher entry barrier than compound patents?

Answer: Usually yes in late-life. Generic manufacturers can sometimes avoid compound claims by using different routes, different forms, or different intermediates, but process claims and product-by-process arguments become more significant when the claimed form is tied to manufacturing steps that the competitor must replicate.

---

Which companies are challenging oxazolidinone drugs with Paragraph IV AND what settlements have occurred?

Answer: Oxazolidinone generic challenges typically concentrate on the largest remaining commercial footprints and on the most patent-protected dosage forms. Parties with generic portfolios that include linezolid and tedizolid follow a playbook: file Paragraph IV against Orange Book-listed patents, leverage the 30-month stay, and resolve via settlement or design-around.

H2 What generic entry risks exist for oxazolidinone drugs?

Answer: Entry risk is driven by:

• Whether the proposed product matches the claimed form or “equivalent” form.
• Whether the ANDA includes a carve-out that is credible against formulation or polymorph patents.
• Whether process patents can be avoided by selecting alternate crystallization and drying routes that still yield acceptable dissolution profiles.

H3 What settlement structures are common in oxazolidinone cases?

Typical U.S. settlement patterns include:

• Agreed launch dates tied to a later final approval date.
• “Covenant not to sue” covering specific patents through a defined period.
• Design-around commitments for formulation or manufacturing steps.

---

What biosimilar risk applies to oxazolidinone antibacterial drugs?

Answer: Biosimilar risk is not a meaningful category for small-molecule oxazolidinone antibiotics. The relevant competitive pathway is generic ANDA entry (small molecule) rather than biosimilar pathways.

---

How does linezolid compare with tedizolid in commercial dynamics and patent-driven competition?

Answer:

• Linezolid: longer established, with a broader history of generic competition and more matured patent timelines. Current competitive pressure tends to be pricing and supply chain driven, with late-life patent disputes still possible where formulation or solid-state patents survive for specific product presentations.
• Tedizolid: newer market presence, with patent estates that more often remain active for longer due to later development and life-cycle filings. Competition is more likely to be shaped by the specific dosage form strengths, IV/oral presentation, and whether generics can avoid solid-state and formulation barriers.

H3 Which patient care segments drive oxazolidinone sales and thus justify continued life-cycle IP?

Sales drivers typically include:

• Hospital-treated gram-positive infections and resistant strains (for example, MRSA and vancomycin-resistant pathogens).
• Step-down therapy and outpatient transition segments where oral dosing is favored.
• Stewardship and infection-control protocols where dosing schedules and tolerability influence prescribing.

---

What FDA pathways and exclusivity regimes govern oxazolidinone generics (ANDA, 505(b)(2), exclusivity effects)?

Answer:

• Generics pursue ANDA for identical active ingredient, dosage form, strength, and route.
• 505(b)(2) can be used for alternative dosing regimens, combination products, or changes in route or formulation, which can alter the exclusivity landscape and patent listing dynamics.

H2 Does 505(b)(2) change the oxazolidinone patent landscape compared with ANDA?

Answer: Yes. 505(b)(2) can rely on literature or findings of safety and effectiveness and may be more flexible for some formulation changes, but it still faces method-of-use and listed-patent obstacles where patents are tied to the NDA’s approved indications.

H3 How do exclusivity and Orange Book listings interact in oxazolidinone cases?

Answer: Even when a patent is not listed for a proposed change, the exclusivity and any non-listed patents still matter. Orange Book-listed patents trigger Hatch-Waxman automatic stays for Paragraph IV; exclusivity can independently block approval timelines.

---

What manufacturing/IP barriers block generic oxazolidinone entry (process and quality attributes)?

Answer: For oxazolidinones, the principal barriers are:

• The ability to reproducibly produce the required solid-state form with stable quality attributes.
• Demonstrating bioequivalence when polymorph/form changes affect dissolution behavior.
• Avoiding infringement of crystallization, drying, and formulation process patents.

H3 What quality attributes are typically tested in oxazolidinone generic development?

Commonly targeted parameters include:

• Dissolution rate and dissolution profile similarity.
• Particle size distribution and morphology.
• Impurity profile and degradation pathways.
• Stability under accelerated and long-term conditions.

---

Key Takeaways

• Oxazolidinone antibacterial patent landscapes are dominated by solid-state forms (polymorphs/salts/prodrugs), formulations, and process/manufacturing claims, not only by the core chemical scaffold.
• U.S. generic entry timing is principally determined by Orange Book-listed patent expiry and any applicable FDA exclusivity tied to the NDA and dosage form/strength.
• Linezolid competition is generally more advanced, with late-stage barriers often shifting to specific product forms and surviving life-cycle IP.
• Tedizolid has a more recent and often more active patent backdrop, with entry risk concentrated in dosage-form-specific and solid-state/formulation-linked claims.
• Paragraph IV and settlements are typically driven by whether a generic can credibly design around the claimed form and manufacturing process without losing dissolution and bioequivalence.

---

FAQs

1) What kinds of patents most frequently block ANDA approvals for oxazolidinone antibiotics?
Formulation and solid-state patents tied to specific polymorphs/hydrates and manufacturing/crystallization steps are the most common late-life blockers.

2) Can a generic oxazolidinone avoid infringement by using a different polymorph?
Only if the alternate form avoids infringement of the claimed “form” and still achieves required dissolution and bioequivalence targets.

3) What is the biggest determinant of generic launch timing for oxazolidinone drugs in the U.S.?
The latest expiry among Orange Book-listed patents for the exact dosage form/strength, plus overlaying FDA exclusivity and any Hatch-Waxman litigation stay.

4) Do oxazolidinones face biosimilar competition risk?
No. Oxazolidinones are small-molecule antibiotics, so competition is primarily generic ANDA entry.

5) What are the main reasons oxazolidinone settlements include “design-around” obligations?
Because infringement risk often centers on product-specific form and process claims that require changed manufacturing conditions or form selection.

---

References (APA)

1. U.S. FDA, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA Hatch-Waxman Act Overview and relevant FDA guidance documents. https://www.fda.gov/